Clinical studies in oral allergen-specific immunotherapy: differences among allergens

Area of Science:

• Allergy and Immunology
• Clinical Therapeutics
• Food Science

Background:

• Oral immunotherapy (OIT) is a primary treatment for food allergies, aiming to induce desensitization.
• Patients undergoing OIT often experience mild to moderate symptoms during treatment.
• The long-term efficacy and safety of OIT, and whether it induces natural tolerance, require further investigation.

Purpose of the Study:

• To evaluate the efficacy and safety of OIT for food allergy treatment.
• To explore novel therapeutic approaches, including combination therapies.
• To assess the potential benefits of OIT combined with omalizumab.

Main Methods:

• Review of existing data on OIT efficacy across different food antigens.
• Examination of recent studies on novel treatments like sublingual and epicutaneous immunotherapy.
• Analysis of combination therapy involving OIT and anti-IgE monoclonal antibody (omalizumab).

Main Results:

• OIT efficacy varies among food antigens, with milk OIT being particularly challenging.
• OIT can induce desensitization but is often accompanied by adverse symptoms.
• Combination therapy with OIT and omalizumab demonstrated increased food threshold doses without adverse reactions.

Conclusions:

• OIT is effective for desensitization but has limitations regarding symptom management and long-term tolerance.
• Novel treatments and combination therapies, such as OIT with omalizumab, show potential for improved food allergy management.
• Further extensive studies are necessary to confirm the long-term safety and benefits of these advanced treatment strategies.